Member Info for AquaeSulis01

Legalwolf, I really don't understand the point you are trying to make, of course PJ has exercised warrants to buy shares (the RNS has told you as much) but he has in addition continued to buy additional shares at full market rate to add to his already considerable holding. What do you imagine happens when warrants are exercised?

The link

https://idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html

skid, I can see a much bigger upside to investors from a properly targeted marketing campaign for Cholbiome. Look at these worldwide figures for type2 diabetes and those sufferers are also prone to high bad cholesterol. When you then consider 25% refuse to take statins, just imagine what the potential sales figures could be with a decent marketing of the product:-
The IDF Diabetes Atlas Ninth edition 2019 provides the latest figures, information and projections on diabetes worldwide.

In 2019,

Approximately 463 million adults (20-79 years) were living with diabetes; by 2045 this will rise to 700 million
The proportion of people with type 2 diabetes is increasing in most countries
79% of adults with diabetes were living in low- and middle-income countries
1 in 5 of the people who are above 65 years old have diabetes
1 in 2 (232 million) people with diabetes were undiagnosed
Diabetes caused 4.2 million deaths
Diabetes caused at least USD 760 billion dollars in health expenditure in 2019 – 10% of total spending on adults
More than 1.1 million children and adolescents are living with type 1 diabetes
More than 20 million live births (1 in 6 live births) are affected by diabetes during pregnancy
374 million people are at increased risk of developing type 2 diabetes

skid, agree the language used re skin is simplistic but none-the-less, it is an asset that can be used if SOH needs funds to market first gen products or develop second generation products in addition to providing long suffering holders with a dividend

There's an awful lot of negativity on the BB despite two very positive RNS's being published. NATE, POW is not a one trick pony like Hurricane Energy and Helium 1. Paul has built an excellent portfolio of projects in different regions across the world and he explains in great detail how the spin out model is designed to work; principally a funding vehicle for direct interest POW projects in lieu of constantly going to the market cap in hand to raise funds like most junior mining companies. Also, the Silver Peak interests may well be sold to an interested third party rather than IPO'd, it has yet to be decided.

Here Paul explains in great detail how the spin out model is designed to work, you are better listening to that than the constant unjustified negative diatribe from bitcoin who was spouting nonsense last year when I saw fit to filter out the noise

https://www.youtube.com/watch?v=de9xYkMpCtY

Isn't the one on the Canadian Exchange an Oil Company?
https://www.bloomberg.com/profile/company/8291175Q:CN

Yep the increase in the oil price since the pessimistic June update that still saw the share price drop to 241.5p augers well for a more bullish report and nice uptick from today's price; here's hoping

In which case Mark8303, the Maritime Sector is now looking very promising for Ceres following the announcement in the telegraph re the Maersk shipping purchase from Hyundai Heavy Shipping who have a MOU with our partner Doosan to use Ceres SOFC.
https://www.telegraph.co.uk/business/2021/08/24/maersk-goes-green-methanol-powered-container-ships/
Maersk goes green with methanol-powered container ships
Order for eight zero-carbon container ships by world's largest container line highlights demand for environmentally friendly sea freight
By
Alan Tovey,
INDUSTRY EDITOR
24 August 2021 • 12:27pm
Maersk ship
The world's biggest shipping company giant has taken a major step towards environmentally friendly sea freight by ordering eight ships that can run on either methanol or traditional fuels.
Maersk has ordered eight vessels each capable of carrying 16,000 standard 20ft shipping containers (known as TEU) from Hyundai Heavy Industries, with deliveries starting in 2024. It has an option for four more ships.
It is the first major order from a shipping line for large ships that can operate with a zero carbon footprint and comes as the industry faces mounting pressure to reduce its environmental footprint.
Shipping is responsible for 3pc of CO2 emissions and the International Maritime Organisation has a 2030 target of cutting emissions to 60pc of their 2008 levels, and halving all emissions by 2050.
Maersk’s new carbon neutral ships, which cost about $175m (£128m) each, will run on green methanol made by combining sustainably produced hydrogen and carbon dioxide captured from renewable sources.
Running on this fuel would cut carbon emissions by about 1m tonnes a year.
However, the “dual fuel” option, which increases the cost of each ship by between 10pc and 15pc, means they can also run on conventional low sulphur fuel.
Soren Skou, the Maersk chief executive, said: “The time to act is now if we are to solve shipping’s climate challenge. This order proves that carbon-neutral solutions are available today across container vessel segments and that Maersk stands committed to the growing number of our customers who look to decarbonise their supply chains.”
The order from such a big operator was a “firm signal to fuel producers that sizeable market demand for the green fuels of the future is emerging at speed”. Maersk accounts for about a fifth of the global container fleet capacity of some 23m TEU.
In February Maersk dipped its toe into green shipping, ordering a methanol-powered “feeder” 2,100 TEU ship that will operate on short northern European routes.
The Danish company said at the time that the vessel “would show the world it can be done” and “kickstart” the market.
Several Maersk customers have backed its order for the eight new ships.
Leyla Ertur at H&M said they were an important step in supporting the fashion chain's climate goals, adding: "We are proud to take part in this pioneer journey.”

or no waves whatsoever

Lifesaving blood pressure checks at every chemist
https://www.express.co.uk/life-style/health/1481094/nhs-blood-pressure-checks-chemist

Just need to stock Cholbiomebp next to the test area for those w=found to have high bp.

VAT applies

skid, Belgrano's assessment of the interview is spot on rather than the inference from Chris that significant new information was given. What you get with an elric podcast is flesh on the bones as opposed to just the bones that a proactive interview will give you; the bones being the RNS worthy data. As regards using a single private investor, that is simply untrue, a proactive interview was held post the RNS release.

https://www.dailymail.co.uk/money/investing/article-9914439/MIDAS-SHARE-TIPS-Poolbeg-Pharma-prove-exciting-opportunity.html?ns_mchannel=rss&ns_campaign=1490&ito=1490#socialLinks

Thanks elric, much appreciated

Assay results seem to be taking around 5 weeks from hole completion so further Creswick update due out next week if that holds good.

Belgrano you are working off old figures. I believe the original axis revenue estimates following elric's interview with Stuart were £9.2M based on 25000 subs at £1 per sachet, the confirmed price is now £1.5 so need a 50% uplift

Over £3.6M raised through warrants and options now; handy little revenue stream whilst waiting for that big discovery

Agree Trek. Worth a listen to Paul Johnson CEO at POW's comments re the cyclical price action for the junior mine sector as a whole
https://www.youtube.com/watch?v=yeauwxCgNV8

Doubt we'll have to wait too long for that catalyst skid. Reminder of what's to come this calendar year from the 5th Aug Trading update (Update re the Seed Health territory extension already notified 7 days later)
"Outlook

The Company is currently working in a number of areas of which a number have the potential to significantly impact on shareholder value. These include:-



1. The publication of a placebo-controlled human study which shows that LPLDL® can achieve similar reductions in total cholesterol and LDL (bad cholesterol) to statins, with no reported side effects. This has been with the editorial board of a peer reviewed journal for a number of months. COVID publications are currently being prioritised by editors but we expect this to be published in H2. Publications on how a product works, its safety and efficacy, are important to pharmaceutical partners who may wish to sell LPLDL® as a drug, or Over the Counter (OTC) in high value hospital, GP, and pharmacy channels.

2. The publication of a study demonstrating prebiotic activity and superior taste profile of a number of SweetBiotix products. The aim is to try to time the release of this publication with our partner announcing news on the manufacturing scale up of SweetBiotix® to maximise market interest.

3. The Company is in discussion with a number of corporate partners who want to acquire rights for its first-generation products in key strategic markets. If successful any one of these has the potential to significantly impact on revenues. Whilst there are no guarantees, we believe that at least one, possibly two, are likely to reach final agreement in H2.

4. The Company currently has a number of Material Transfer Agreements in place with corporate partners who are evaluating the use of different types of SweetBiotix in their products. This work was impacted in H2 2020 and H1 2021 as companies were unable to carry out development work in their laboratories with home working due to COVID. This work has now recommenced and we should expect news in H2.

5. The Company succeeded in developing an approach which allows us to manufacture microbiome modulators at scale in H1. This was a significant technical challenge. Whilst current work is focused on developing prebiotics which selectively enhance the growth and effect of the most commercially successful probiotics, it is likely to be applicable across a broad range of bacteria present in the microbiome. This creates the potential to manufacture prebiotic products to scale which can change the relative abundance of specific microbial species linked to disease, in essence precision engineering the microbiome. If proven, this has the potential to create microbiome based products across multiple therapeutic areas.

6. The success of a number of products launches has led to requests for new products and extension of territories with a number of existing partners. Discussions are ongoing and further news will be announced"

RNS does appear to have been drafted in a hurry by some very busy people but is extremely positive. The proposed starting price for axisbiotix of £1.50 reflects a high level of confidence in achieving the starting constrained subscription level of 25000 following the targeted marketing to come and will generate revenues in excess of those calculated by elric following the podcasts. Approvals already received from US, UK and EU means last hurdle to launch has now been removed and confirmation of the skinbiotix timelines, irrespective of the freudian slip, was also very reassuring and I consider has significantly de-risked my investment here. As I presume this was also the expected half year trading update, I would have expected to have heard something about the progress on R&D, cleanbiotix and medibiotix, perhaps one for elric to tease out and put in the public domain